Health economics and quality of life in cancer trials: report based on a UKCCCR workshop
1998

Health Economics and Quality of Life in Cancer Trials

publication Evidence: moderate

Author Information

Author(s): R Fitzpatrick, L Davies

Primary Institution: University of Oxford; University of York

Hypothesis

When should health economics and quality of life assessments be included in cancer clinical trials?

Conclusion

Incorporating health economics and quality of life assessments into cancer trials is essential but complex, requiring careful consideration of methodology and participant burden.

Supporting Evidence

  • Quality of life measures are essential for understanding the impact of cancer treatments on patients.
  • Health economic evaluations can inform decisions about the value of new treatments.
  • Quality of life and economic data often address distinct questions in clinical trials.

Takeaway

This study talks about how important it is to think about patients' quality of life and the costs of treatments when doing cancer research. It helps make sure that new treatments are not just effective but also good for patients.

Methodology

The paper summarizes discussions from a workshop involving clinicians, health economists, and other experts to address the integration of health economics and quality of life in cancer trials.

Potential Biases

Potential biases may arise from the subjective nature of quality of life assessments and the varying perspectives of patients and healthcare providers.

Limitations

There is no consensus on when to include quality of life and economic data in trials, and the burden of additional data collection may affect trial feasibility.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication